Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 24 04:00PM ET
77.27
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-1.15 Insider Own6.54% Shs Outstand105.58M Perf Week0.99%
Market Cap8.16B Forward P/E72.63 EPS next Y1.06 Insider Trans-4.66% Shs Float98.68M Perf Month2.25%
Income-110.87M PEG- EPS next Q-0.19 Inst Own83.86% Short Float2.96% Perf Quarter4.40%
Sales513.93M P/S15.87 EPS this Y62.42% Inst Trans1.75% Short Ratio2.64 Perf Half Y16.27%
Book/sh6.15 P/B12.56 EPS next Y293.88% ROA-15.09% Short Interest2.92M Perf Year25.58%
Cash/sh4.52 P/C17.09 EPS next 5Y- ROE-18.07% 52W Range45.50 - 84.89 Perf YTD7.89%
Dividend Est.- P/FCF- EPS past 5Y12.47% ROI-18.11% 52W High-8.98% Beta1.00
Dividend TTM- Quick Ratio5.00 Sales past 5Y7617.73% Gross Margin92.82% 52W Low69.82% ATR (14)2.41
Dividend Ex-Date- Current Ratio5.12 EPS Y/Y TTM52.23% Oper. Margin-25.67% RSI (14)60.15 Volatility2.92% 3.36%
Employees610 Debt/Eq0.03 Sales Y/Y TTM65.45% Profit Margin-21.57% Recom1.44 Target Price93.87
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q66.01% Payout- Rel Volume0.00 Prev Close77.27
Sales Surprise2.47% EPS Surprise49.59% Sales Q/Q52.00% EarningsAug 07 BMO Avg Volume1.11M Price77.27
SMA204.38% SMA509.27% SMA20016.63% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Jan-03-24Initiated Robert W. Baird Outperform $83
Dec-11-23Initiated TD Cowen Outperform $75
Apr-20-23Initiated Morgan Stanley Overweight $80
Aug-22-22Downgrade Goldman Buy → Neutral $64 → $49
Jul-07-22Initiated Mizuho Buy $74
Jun-14-22Initiated UBS Buy $75
Apr-22-22Initiated Piper Sandler Neutral $59
Feb-16-22Initiated Goldman Buy $64
Sep-23-21Initiated Needham Buy $55
Dec-15-20Initiated BofA Securities Buy $40
Jul-24-24 08:00AM
Jul-09-24 09:55AM
Jun-24-24 09:52AM
Jun-20-24 02:37PM
Jun-19-24 10:27AM
06:27AM Loading…
06:27AM
Jun-18-24 04:22PM
01:34PM
07:30AM
07:30AM
Jun-10-24 08:00AM
Jun-06-24 11:31AM
May-30-24 06:00AM
May-29-24 08:00AM
May-27-24 06:34PM
06:13PM Loading…
06:13PM
May-23-24 08:00AM
May-08-24 03:44PM
11:43AM
08:00AM
03:13AM
May-07-24 09:18AM
09:12AM
08:40AM
08:16AM
07:37AM
07:30AM
Apr-30-24 08:00AM
Apr-25-24 10:01AM
Apr-24-24 04:01PM
11:36AM Loading…
11:36AM
11:31AM
Apr-22-24 11:10AM
Apr-17-24 08:46PM
09:44AM
09:21AM
07:36AM
Apr-16-24 04:06PM
04:00PM
12:19PM
09:08AM
07:14AM
07:00AM
Mar-19-24 08:30AM
Mar-12-24 01:16AM
Mar-06-24 08:00AM
Mar-04-24 08:28PM
Feb-28-24 05:01AM
Feb-27-24 08:00AM
Feb-23-24 11:59AM
08:41AM
Feb-22-24 07:59AM
07:53AM
07:30AM
Feb-15-24 10:00AM
Feb-13-24 11:51AM
Feb-10-24 03:07PM
Feb-08-24 08:00AM
Feb-05-24 11:11PM
Jan-18-24 09:01PM
Jan-12-24 07:02PM
09:23AM
Jan-05-24 11:02AM
Jan-02-24 08:00AM
Jan-01-24 09:55AM
Dec-20-23 02:15PM
Dec-19-23 12:00PM
Dec-16-23 03:02PM
Dec-13-23 01:11PM
Dec-05-23 08:00AM
Nov-23-23 09:55AM
Nov-15-23 04:31PM
08:00AM
01:03AM
Nov-07-23 09:55AM
Nov-03-23 02:51PM
Nov-02-23 10:17AM
07:40AM
07:30AM
Oct-31-23 08:00AM
Oct-29-23 07:00AM
Oct-26-23 10:02AM
08:00AM
Sep-20-23 08:00AM
05:05AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-04-23 08:40AM
08:00AM
Aug-03-23 08:55AM
07:53AM
07:30AM
Jul-28-23 08:00AM
Jun-20-23 02:13PM
Jun-09-23 11:30AM
Jun-05-23 08:00AM
May-31-23 08:00AM
May-29-23 07:26AM
May-08-23 10:04AM
09:19AM
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RIGGS RORY BDirectorJun 24 '24Option Exercise16.8620,000337,200121,062Jun 25 06:04 PM
RIGGS RORY BDirectorJun 24 '24Sale75.574,462337,193116,600Jun 25 06:04 PM
VAN NOSTRAND ROBERT LDirectorJun 18 '24Option Exercise16.8620,000337,20029,690Jun 21 06:00 PM
VAN NOSTRAND ROBERT LDirectorJun 18 '24Sale75.9120,0001,518,1999,690Jun 21 06:00 PM
Mates SharonChairman and CEOApr 24 '24Option Exercise17.2620,020345,6181,070,329Apr 25 05:08 PM
RIGGS RORY BDirectorMar 20 '24Option Exercise18.5620,000371,20099,235Mar 22 04:12 PM
Mates SharonChairman, President & CEOMar 11 '24Sale65.2120,5651,341,1231,050,309Mar 11 08:33 PM
Hineline Lawrence J.SVP of Finance, CFOMar 11 '24Sale65.9610,121667,5870Mar 11 08:33 PM
Halstead MichaelEVP and General CounselMar 11 '24Sale65.977,345484,5370Mar 11 08:32 PM
Neumann MarkEVP, Chief Commercial OfficerMar 11 '24Sale65.617,345481,93129,700Mar 11 08:31 PM
Durgam Suresh K.EVP, Chief Medical OfficerMar 11 '24Sale65.593,712243,48219,803Mar 11 08:31 PM
Hineline Lawrence J.SVP of Finance, CFOMar 10 '24Option Exercise56.734,539257,4974,539Mar 11 08:33 PM
Mates SharonChairman, President & CEOMar 07 '24Sale66.5040,7122,707,2771,050,309Mar 11 08:33 PM
Hineline Lawrence J.SVP of Finance, CFOMar 07 '24Sale66.6013,132874,5600Mar 11 08:33 PM
Neumann MarkEVP, Chief Commercial OfficerMar 07 '24Sale66.5713,132874,17929,700Mar 11 08:31 PM
Halstead MichaelEVP and General CounselMar 07 '24Sale66.1513,132868,6980Mar 11 08:32 PM
Durgam Suresh K.EVP, Chief Medical OfficerMar 07 '24Sale66.566,450429,30816,170Mar 11 08:31 PM
VAN NOSTRAND ROBERT LDirectorFeb 27 '24Option Exercise18.5620,000371,20029,611Feb 28 07:41 PM
VAN NOSTRAND ROBERT LDirectorFeb 27 '24Sale72.9320,0001,458,6509,611Feb 28 07:41 PM
MARCUS JOEL SDirectorFeb 26 '24Option Exercise48.9336,7571,798,67865,990Feb 27 07:57 PM
Hineline Lawrence J.SVP of Finance, CFOFeb 26 '24Option Exercise36.895,882216,9875,882Feb 27 08:00 PM
MARCUS JOEL SDirectorFeb 26 '24Sale68.6826,3281,808,25339,662Feb 27 07:57 PM
Mates SharonChairman, President & CEOFeb 26 '24Sale69.7922,5901,576,4641,050,309Feb 27 07:59 PM
Hineline Lawrence J.SVP of Finance, CFOFeb 26 '24Sale69.4313,337925,9610Feb 27 08:00 PM
Neumann MarkEVP, Chief Commercial OfficerFeb 26 '24Sale70.137,907554,49129,700Feb 27 07:58 PM
Halstead MichaelEVP and General CounselFeb 26 '24Sale69.537,907549,7840Feb 27 08:00 PM
Durgam Suresh K.EVP, Chief Medical OfficerFeb 26 '24Sale70.174,112288,5349,488Feb 27 07:58 PM
Mates SharonChairman, President & CEOFeb 02 '24Sale67.0733,8852,272,6941,050,309Feb 05 06:10 PM
Neumann MarkEVP, Chief Commercial OfficerFeb 02 '24Sale67.1511,860796,36729,700Feb 05 06:07 PM
Halstead MichaelEVP and General CounselFeb 02 '24Sale66.4211,860787,7190Feb 05 06:13 PM
Hineline Lawrence J.SVP of Finance, CFOFeb 02 '24Sale66.6211,183745,0370Feb 05 06:05 PM
Durgam Suresh K.EVP, Chief Medical OfficerFeb 02 '24Sale67.196,167414,3555,693Feb 05 06:02 PM
Mates SharonChairman, President & CEOJan 18 '24Option Exercise16.8667,9171,145,0811,118,226Jan 18 07:47 PM
Mates SharonChairman, President & CEOJan 18 '24Sale65.1967,9174,427,8481,050,309Jan 18 07:47 PM
Mates SharonChairman, President & CEOJan 17 '24Option Exercise16.8648,084810,6961,098,393Jan 18 07:47 PM
Mates SharonChairman, President & CEOJan 17 '24Sale66.2448,0843,185,0621,050,309Jan 18 07:47 PM
Mates SharonChairman, President & CEOJan 16 '24Option Exercise16.8675,3611,270,5861,125,670Jan 18 07:47 PM
Mates SharonChairman, President & CEOJan 16 '24Sale67.2575,3615,067,9821,050,309Jan 18 07:47 PM
Halstead MichaelEVP and General CounselJan 11 '24Option Exercise13.6050,000680,05150,000Jan 12 06:02 PM
Halstead MichaelEVP and General CounselJan 11 '24Sale66.8350,0003,341,6990Jan 12 06:02 PM
Durgam Suresh K.EVP, Chief Medical OfficerJan 02 '24Option Exercise19.8762,2821,237,54362,282Jan 04 07:54 PM
Durgam Suresh K.EVP, Chief Medical OfficerJan 02 '24Sale70.6062,2824,397,1130Jan 04 07:54 PM
Durgam Suresh K.EVP, Chief Medical OfficerDec 13 '23Sale65.0021,2621,382,0300Dec 15 05:01 PM
Neumann MarkEVP, Chief Commercial OfficerNov 06 '23Option Exercise23.9426,754640,49172,093Nov 08 05:31 PM
Neumann MarkEVP, Chief Commercial OfficerNov 06 '23Sale55.6342,3932,358,15229,700Nov 08 05:31 PM
Mates SharonChairman, President & CEOSep 19 '23Sale54.1744,4132,405,8521,050,309Sep 19 08:40 PM
Mates SharonChairman, President & CEOSep 18 '23Sale53.7655,5872,988,2131,094,722Sep 19 08:40 PM
Neumann MarkEVP, Chief Commercial OfficerAug 07 '23Option Exercise18.5955,3001,028,027100,639Aug 09 06:05 PM
Neumann MarkEVP, Chief Commercial OfficerAug 07 '23Sale58.7955,3003,251,08745,339Aug 09 06:05 PM